Cargando…

Partial Lipodystrophy and LMNA p.R545H Variant

Laminopathies are disorders caused by LMNA gene mutations, which selectively affect different tissues and organ systems, and present with heterogeneous clinical and pathological traits. The molecular mechanisms behind these clinical differences and tissue specificity have not been fully clarified. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magno, Silvia, Ceccarini, Giovanni, Barison, Andrea, Fabiani, Iacopo, Giacomina, Alessandro, Gilio, Donatella, Pelosini, Caterina, Rubegni, Anna, Emdin, Michele, Gatti, Gian Luca, Santorelli, Filippo Maria, Sessa, Maria Rita, Santini, Ferruccio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963176/ https://www.ncbi.nlm.nih.gov/pubmed/33803191 http://dx.doi.org/10.3390/jcm10051142

Ejemplares similares

Atypical Progeroid Syndrome and Partial Lipodystrophy Due to LMNA Gene p.R349W Mutation
por: Magno, Silvia, et al.
Publicado: (2020)

Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation
por: Ceccarini, G., et al.
Publicado: (2022)

Circulating Levels of MiRNAs From 320 Family in Subjects With Lipodystrophy: Disclosing Novel Signatures of the Disease
por: Dattilo, Alessia, et al.
Publicado: (2022)

SAT-087 Familial Generalized Lipodystrophy in Two Siblings Due to Homozygous p.Arg545His LMNA Mutation
por: Patni, Nivedita, et al.
Publicado: (2019)

Metreleptin therapy in LMNA-linked lipodystrophies
por: Vatier, Camille, et al.
Publicado: (2015)

Multisystem Progeroid Syndrome With Lipodystrophy, Cardiomyopathy, and Nephropathy Due to an LMNA p.R349W Variant
por: Hussain, Iram, et al.
Publicado: (2020)

Canagliflozin on top of dual renin-angiotensin system blockade in a woman with partial acquired lipodystrophy, type 2 diabetes and severely proteinuric chronic kidney disease: a case report
por: Biancalana, Edoardo, et al.
Publicado: (2023)

Homozygous LMNA p.R582H pathogenic variant reveals increasing effect on the severity of fat loss in lipodystrophy
por: Soyaltin, Utku Erdem, et al.
Publicado: (2020)

Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis
por: Sahinoz, Melis, et al.
Publicado: (2018)

Hepatic Steatosis Resulting From LMNA-Associated Familial Lipodystrophy
por: Mahdi, Layth, et al.
Publicado: (2020)

Congenital Generalized Lipoatrophy (Berardinelli-Seip Syndrome) Type 1: Description of Novel AGPAT2 Homozygous Variants Showing the Highly Heterogeneous Presentation of the Disease
por: Ceccarini, Giovanni, et al.
Publicado: (2020)

A new mutation in the CAVIN1/PTRF gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature
por: Mancioppi, Valentina, et al.
Publicado: (2023)

Novel Heterozygous LMNA Variants Causing Familial Partial Lipodystrophy, Dunnigan Variety
por: Wadhwa, Akhilesh, et al.
Publicado: (2021)

Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants
por: Vasandani, Chandna, et al.
Publicado: (2022)

SUN-600 Presence of LMNA p.R582H Pathogenic Variant in Homozygous State Demonstrates Gene Dosage Effect on the Severity of Fat Loss in Lipodystrophy
por: Soyaltin, Utku Erdem, et al.
Publicado: (2020)

Ketogenic Diet and Weight Loss: Is There an Effect on Energy Expenditure?
por: Basolo, Alessio, et al.
Publicado: (2022)

Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
por: Fernandez-Pombo, Antia, et al.
Publicado: (2023)

European lipodystrophy registry: background and structure
por: von Schnurbein, Julia, et al.
Publicado: (2020)

Body Composition And Bone Mineral Differences According to Lamin A (LMNA) Genotype in Familial Partial Lipodystrophy Type 2
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

Familial partial lipodystrophy and proteinuric renal disease due to a missense c.1045C > T LMNA mutation
por: Fountas, Athanasios, et al.
Publicado: (2017)

Waist circumference is independently associated with liver steatosis and fibrosis in LMNA-related and unrelated Familial Partial Lipodystrophy women
por: Viola, Luiz F., et al.
Publicado: (2023)

Treatment of Hypothyroid Patients With L-Thyroxine (L-T4) Plus Triiodothyronine Sulfate (T3S). A Phase II, Open-Label, Single Center, Parallel Groups Study on Therapeutic Efficacy and Tolerability
por: Santini, Ferruccio, et al.
Publicado: (2019)

Looking at New Unexpected Disease Targets in LMNA-Linked Lipodystrophies in the Light of Complex Cardiovascular Phenotypes: Implications for Clinical Practice
por: Mosbah, Héléna, et al.
Publicado: (2020)

SUN-LB111 Comparison of Phenotype and Metabolic Abnormalities Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants
por: Vasandani, Chandna, et al.
Publicado: (2020)

Variable Expressivity and Allelic Heterogeneity in Type 2 Familial Partial Lipodystrophy: The p.(Thr528Met) LMNA Variant
por: Araújo-Vilar, David, et al.
Publicado: (2021)

Variable Expressivity in Type 2 Familial Partial Lipodystrophy Related to R482 and N466 Variants in the LMNA Gene
por: Araújo-Vilar, David, et al.
Publicado: (2021)

A subtype of laminopathies: Generalized lipodystrophy‐associated progeroid syndrome caused by LMNA gene c.29C>T mutation
por: Huang, Shipeng, et al.
Publicado: (2023)

Complement Factor D (adipsin) Levels Are Elevated in Acquired Partial Lipodystrophy (Barraquer–Simons syndrome)
por: Corvillo, Fernando, et al.
Publicado: (2021)

SUN-593 Variants in Known Monogenic Causal Genes of Hypertriglyceridemia Are Not Major Contributors for Hypertriglyceridemia in Lipodystrophy Due to a LMNA Mutation
por: Ueda, Masako, et al.
Publicado: (2020)

Limb-girdle muscular dystrophy with severe heart failure overlapping with lipodystrophy in a patient with LMNA mutation p.Ser334del
por: Madej-Pilarczyk, Agnieszka, et al.
Publicado: (2016)

Correction to: Immunological features of patients affected by Barraquer-Simons syndrome
por: Corvillo, Fernando, et al.
Publicado: (2020)

Immunological features of patients affected by Barraquer-Simons syndrome
por: Corvillo, Fernando, et al.
Publicado: (2020)

LDL-cholesterol lowering effect of a new dietary supplement: an open label, controlled, randomized, cross-over clinical trial in patients with mild-to-moderate hypercholesterolemia
por: Magno, S., et al.
Publicado: (2018)

Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report
por: Pedicelli, Stefania, et al.
Publicado: (2020)

Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype
por: Volkening, Kathryn, et al.
Publicado: (2021)

Lipodystrophy as a Late Effect after Stem Cell Transplantation
por: Tews, Daniel, et al.
Publicado: (2021)

Progeroid laminopathy with restrictive dermopathy-like features caused by an isodisomic LMNA mutation p.R435C
por: Starke, Sven, et al.
Publicado: (2013)

Severe aortic stenosis during leptin replacement therapy in a patient with generalized lipodystrophy‐associated progeroid syndrome due to an LMNA variant: A case report
por: Sasako, Takayoshi, et al.
Publicado: (2022)

Diagnosis and treatment of lipodystrophy: a step-by-step approach
por: Araújo-Vilar, D., et al.
Publicado: (2018)

Galectin-3 and Risk for Cancer or Heart Failure: Does Sex Matter?
por: Fabiani, Iacopo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vudm4t2v06uf2a3j7l0a8f85nq